The purpose of this review is to provide a brief overview of bioreactor-based culture systems as alternatives to conventional two-and three-dimensional counterparts. The role, challenges, and future aspirations of bioreactors in the musculoskeletal field (e.g., cartilage, intervertebral disc, tendon, and bone) are discussed. Bioreactors, by recapitulating physiological processes, can be used effectively as part of the initial in vitro screening, reducing that way the number of animal required for preclinical assessment, complying with the 3R principles and, in most cases, allowing working with human tissues. The clinical significance of bioreactors is that, by providing more physiologically relevant conditions to customarily used two-and three-dimensional cultures, they hold the potential to provide a testing platform that is more predictable of a whole tissue response, thereby facilitating the screening of treatments before the initiation of clinical trials. ß
With a growing acceptance that two-dimensional (2D) in vitro models are an oversimplification of the human body response and animal models do not, in most cases, represent human conditions, more complex systems are needed to recapitulate human physiology/ pathophysiology. 1, 2 Although three-dimensional (3D) cell culture systems have shown promise, they fail to completely recapitulate the complexity of native tissues (i.e., including all cell types and acellular extracellular matrix components involved). [2] [3] [4] Therefore, whole tissues and even whole organs have been used as advanced ex vivo models. Over the last decades, bioreactors have been successfully used to further improve in vitro and ex vivo culture conditions; to investigate fundamental questions on specific cell functions and tissue development; and to develop standardized, up-scalable, and safe tissue growth systems. A "bioreactor" can be broadly defined as a system that allows the culture of cells or tissues under defined biological conditions. Bioreactors have attracted a growing interest in the musculoskeletal field, as attested by the number of manuscripts published over the last decades (Fig. 1) . Several excellent reviews summarize the evolution of the field in recent years. [5] [6] [7] [8] [9] [10] Here, we will focus on bioreactor systems that transmit a mechanical stimulus, as this is a key parameter in the homeostasis of various musculoskeletal tissues, such as bone, cartilage, tendon, and intervertebral disc. By testing regenerative therapies under conditions that are closer to the ones encountered in vivo, bioreactors can provide a useful screening tool for the evaluation of various cell types, biomaterials, drugs, or tissue engineered products prior to animal testing.
The goal of this short contribution is not to give a comprehensive review on bioreactors and whole tissue cultures, but rather to open a discussion on the various systems used to evaluate biomaterials, drugs, and cell therapies that could have a higher relevance for humans compared to conventional 2D and 3D cultures and in certain cases to animal experimentation. Selected examples on the use of bioreactor systems and whole tissue cultures in the musculoskeletal field, including applications to cartilage, intervertebral disc, tendon, and bone are provided. This short review also provides a brief overview of available systems as alternative for conventional cultures. Selected examples of both the use of model systems to study physiology and disease, as well as systems to study tissue engineering strategies, are presented. The relevance of bioreactors and whole tissue cultures to in vitro, in vivo studies, and the 3Rs principles is examined. The last section provides a summary and an outlook of the research field. appears important to evaluate new therapies in a relevant mechanically-loaded setting. Bioreactors that apply shear force, perfusion, hydrostatic pressure, compression, and combinations of these have been used to study chondrocyte matrix synthesis, chondrogenesis of mesenchymal stem cells (MSCs) and to produce tissue-engineered cartilaginous grafts. [8] [9] [10] 12 Main developmental steps toward models of cartilage physiology and tissue engineering are summarized in Table 1 . These studies have cumulatively shown that mechanical stimulation promotes extracellular matrix formation. In the cartilage tissue-engineering field, bioreactors can be used to address questions such as optimal cell source, density, carrier, expansion protocol, and culture supplements.
Bioreactors can also help to better understand the mechano-biological interplay in physiology, disease, and repair. Since time and cost-effectiveness are key aspects in the translation of tissue-engineered approaches, one-step procedures in combination with appropriate rehabilitation programs could have a strong potential for translation. Bioreactors can help determining optimal post-operative physical and molecular therapy dosages in a physiologically relevant environment. For instance, bioreactor-based studies would support the use of cyclic shear loading in physical therapies, since this type of loading has been shown to be essential to achieve cartilage-like tissue comprising a top lubricin-rich layer conducive to gliding. 13 This type of loading could be used alone or in combination with cyclic compression (e.g., 5% compression and 5% shear at 1 Hz, 1 h/day for 4 weeks), which has been shown to promote the synthesis of transforming growth factor-b (TGF-b) by mesenchymal stem cells, further triggering chondrogenesis. 14, 15 So, what is still missing? So far, synthetic materials have been used to transfer load to tissues or tissueengineered constructs, but more recent models have reproduced cartilage-on-cartilage friction. 16 Moreover, most in vitro loading experiments were performed using standard, low viscosity culture media, but a synovial fluid substitute would be more relevant. Bioreactors could potentially also be used to assess how changes in synovial fluid composition in diseased joints affect cartilage repair capacity. 17 Whole joint mechanically loaded models may be relevant to broaden the investigations to the ligaments as well. 18 With the growing awareness of the involvement of the subchondral bone in osteoarthritis, bioreactor-based ex vivo osteochondral models (comprising a cartilage and a bone part) may represent a very interesting tool to screen therapies prior animal testing. 19, 20 Addition of mechanical loading to such models represents an exciting future advance for the evaluation of new treatments.
Intervertebral Disc Bioreactors and Whole Organ Cultures
The intervertebral disc (IVD) is responsible for the flexibility of the spine and undergoes a complex loading pattern, including flexion/extension, lateral bending, and torsion. Loading plays also a key role in the diffusion of nutrients and metabolic waste removal since IVDs are pretty much avascular. Taken these mechanical and nutritional aspects into account, the limitations of conventional 2D cell culture models appear evident. Hence, 3D carriers, primarily hydrogels, have been used to encapsulate nucleus pulposus (NP) cells. Disc tissue cultures would allow cell maintenance in their native environment, but unlike cartilage explants, IVD tissues undergo strong swelling, and subsequent loss of structure and function, when kept in standard culture conditions. Hypertonic culture medium and fiber jackets have been used to effectively limit the swelling of NP cores, 21 but the most common solution is to keep whole IVDs in cultures either with or without external load. For instance, the group of Mwale has investigated the efficacy of the link-N in promoting proteoglycan synthesis in vitro, 22 ex vivo (on whole human IVDs under confined swelling without application of external load) 23 and in in vivo models. 24 In other studies, it has been shown that exposure of stem cells to the specific (hypoxic, acidic, hyperosmotic) IVD environment in combination with an appropriate carrier (i.e., thermoreversible hyaluronan hydrogel) could trigger differentiation toward the disc phenotype without the need of exogenous growth factor supplementation. 25 Advanced in vitro models have also been developed in the quest to tissue engineer whole IVDs. 26 Since several decades, bioreactors have been used to culture IVDs under defined nutritional and mechanical conditions (see Gantenbein et al. for an up-to-date comprehensive review). 27 IVD bioreactors helped to elucidate the contribution of nutritional and mechanical parameters in healthy IVDs and early stages of disc degeneration. For instance, Illien-J€ unger et al. 28 have shown that a combination of limited nutrition 
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(e.g., in medium with half the concentration of glucose) and high frequency (10 Hz) loading induces a degenerative cascade in the IVD.Bioreactor systems with increasing degree of complexity have been developed with loading ranging from static, intermittent static, dynamic uniaxial cyclic to biaxial cyclic loads (refer to Table 2 for further details). Bioreactors have also been used to assess the performance of nucleus pulposus and annulus fibrous repair strategies under relevant mechanical loading conditions in preparation to large animal model testing. 29, 30 For instance, these studies have proven the ability of dried urethane-based biomaterials to rehydrate inside the disc and have helped to optimize the composition of fibrin-genipin hydrogels to withstand the pressure resulting from physiological loading of large IVDs.
So, what is still missing? Since pain can also originate in the structures surrounding the IVD (e.g., facet joints), further developments of existing IVD models, comprising ligaments and facet joints, are still needed. Furthermore, as there is evidence that painful IVDs can result from inflammation, in vitro 2D inflammation models have been widely used to assess molecular pathways that are involved and test molecular treatments based on inhibitors targeting these pathways. 31 More recently, ex vivo models of inflammation have been developed to investigate degenerative changes associated with inflammation and assess treatments to prevent the progression of the same. 32, 33 Finally, there is the need to develop more physiological motion patterns, for instance by substituting axial compression with bending. Advanced systems comprising six degrees of freedom, such as the ones developed by the group of Costi et al. to assess the mechanical behavior of human IVDs with varying degree of degeneration, 34 hold a great promise for the future.
Tendon and Ligament Mechanical Stimulation
Tendons and ligaments are dense, highly aligned and viscoelastic connective tissues, continuously under mechanical loading. Tendons are responsible for transmitting mechanical forces from muscle to bone, whilst ligaments transmit forces between bones. Following injury, rehabilitation regimes for both tissues require short immobilization and early stretching exercises to reduce swelling and to avoid adhesions/fibrosis. 35, 36 To a greater extend in tendons than in ligaments, efficient load transmission depends heavily on the highly aligned hierarchical structure of collagen fibrils and fibers. 37 For this reason, tissue engineering therapies have primarily focused in the development of hierarchical/anisotropic tissue facsimiles. [38] [39] [40] However, numerous studies have demonstrated that alignment alone is not sufficient and more biomimetic approaches should be employed for functional repair and regeneration. For example, a study suggested that electro-spun fiber diameter may be more important than fiber alignment in mesenchymal stem cell differentiation toward tendon/ligament lineage. 41 Another study suggested that surface topography/substrate rigidity should be fine-tuned to maintain tenogenic phenotype in culture. 42 Most importantly, a study demonstrated that tenocytes, in the absence of mechanical stimulation, aligned perpendicularly to the orientation of anisotropic electro-spun fibers, 43 clearly suggesting the need for mechanical loading.
Mechanical loading can be provided in a static 44 or dynamic manner, with cyclic dynamic stretching being more physiologically relevant, 45 as loading regimes can be tailored as needed and more effectively represent daily movement (Table 3) . Ligaments, however, present a greater challenge, as their mechanical requirements can include multi-axial or rotational forces. Nonetheless, several studies report growth of bone MSCs and ligament fibroblasts on mechanically stimulated scaffolds. 46, 47 Dynamic uniaxial stretching increases the expression of tendon-specific genes and proteins (e.g., collagen type I, collagen type III, scleraxis, tenascin-C) in both tenocytes and stem cells 48, 49 and can induce cell and extracellular matrix alignment. 50 In tendon-derived stem cells, although lower strains induce tenogenic differentiation, higher strain values can induce osteogenic, adipogenic, and chondrogenic differentiation. 51 Similarly, high strain or prolonged stretching is associated with the presence of inflammatory mediators, 52 showing that mechanical loading can also be used for the development of in vitro pathophysiology models, thereby becoming a critical tool in development of drugs and alternatives to commonly used animal models. Bioreactors can also be used to provide pre-implantation conditioning of cell-seeded scaffolds to improve the mechanical properties of the construct. 53 Furthermore, dynamic culture systems of increasing complexity that combine mechanical loading with topographical cues 52 or growth factor supplementation 54 are very promising and pave the way for the development of more physiologically relevant multifactorial approaches.
Despite all of the promising results, the mechanical stimulation protocols, for both tendon and ligament, vary widely in terms of culture substrate (topography, architecture, synthetic, or natural material), loading regime (strain, frequency, duration), and cell source (be it the type of tendon/ligament or other tissues). This heterogeneity hinders the progress in the field, as studies are not comparable. Therefore, standardization of protocols is of paramount importance, not only for the use of bioreactors, but also for the subsequent investigation of cell phenotype commitment at the experimental endpoints. It is also important to consider that current systems do not allow for reliable testing of a large sample number in an inexpensive manner.
Bone Bioreactors and Explant Cultures
Bone is a mechanically loaded and highly vascularized tissue and these two parameters are key to maintain bone viable. Ex vivo bone explant models (including metatarsals, femoral heads, calvaria, mandibular slices, and trabecular cores) have been used to study cartilage and bone physiology, stem cell driven bone repair and mechano-regulation, as recently reviewed by Marino et al. and Abubakar et al. 55, 56 In these settings, the different cell types were maintained in their native environments and whole bones or bone cores were cultivated with or without external load. Fluid flow and perfusion have been widely used to improve viability and matrix synthesis of both bone explants and bone tissue-engineered constructs (Table 4) . 57, 58 More recent systems have successfully used a combination of dynamic mechanical stimulation (e.g., cyclic compression) and perfusion to keep bone core viable for several weeks. All these pioneering studies support the fact that bone viability and activity is promoted by mechanical stimuli. Moreover, it has been shown that cyclic mechanical load had a direct impact on the architecture and mechanical properties of ex vivo cultured bone cores. 59 "In vivo bioreactors" have also been proposed as a way to prepare bone and cartilage grafts, 60 but this goes beyond the scope of this review.
Perfusion compression bioreactors have been used to investigate endochondral bone formation. 61 Cyclic mechanical loading bioreactors have been applied to investigate a fibrin-based model of hematoma, which simulated the initial phases of fracture healing. 62 Further developments of bioreactors for bone studies include high throughput flow perfusion systems. 63 An important aspect is the effective perfusion of 3D structures. In a recent study, Bouet et al. 64 have optimized the 3D structure of ceramic scaffolds to culture bone cells under dynamic compression and perfusion. Unlike previous setups, the tight fitting of the scaffold within the culture system together with a smart scaffold design (i.e., a porous core surrounded by dense walls) constrained the fluid flow inside the scaffold and perfusion was applied perpendicularly to the mechanical load. This provided a homogeneous fluid flow conducive to spatially homogenous bone grafts. By providing an experimental setup that mimics more closely the cell environment found in living bone, bioreactor systems can provide a useful screening tool to investigate in a controlled environment the response of multiple cell types (osteoblasts, osteoclasts, osteocytes, endothelial cells, stem cells) to specific stimuli. Bioreactors may also be used to optimize the type, timing and dosage of physical stimuli to foster fracture healing. 65 Finally, the implementation of an immunological response in bone bioreactors is also an interesting outlook. 66, 67 
BIOREACTORS AS THE MISSING LINK BETWEEN IN VITRO AND IN VIVO STUDIES
2D cell cultures on tissue-culture plastic have been the most widely used setup for in vitro screening of novel biomaterials, drugs, cell, and tissue engineered therapies. The main advantages of 2D cell cultures are their excellent control over culture conditions, simplicity, rapidity, high throughput, availability of standard tissue culture plates in various formats, large panel of biochemical and molecular tools, good reproducibility, and relative low cost.
3D cell cultures represent a step forward toward more relevant models over 2D cultures on tissueculture plastic. For instance, pellet/micro-mass cultures have become a reference for in vitro evaluation of stem cell chondrogenesis and alginate beads and agarose gels have been widely used as three-dimensional carriers for nucleus pulposus disc cells and chondrocytes, respectively. Nonetheless, even these 3D cell culture models are still an over-simplification of the targeted tissue/organ: Cells are not in their native environment, that is, surrounded by the extracellular matrix and important parameters such as diffusion and mechanical loading are absent or not representative of native tissue environment. To improve the assessment of new therapies and their potential translation, there is the need for in vitro models with increased complexity that better Bioreactors have been used to maintain cells and tissues viable and functional under defined nutritional and mechanical conditions. Bioreactors provide a unique opportunity to study the interplay between biological and mechanical stimuli, such as the loading-induced stimulation of TGF-b resulting in chondrogenesis of stem cells 14 and the combined effect of limited nutrition and high frequency loading on IVD degeneration. 29 By providing a more realistic scenario, bioreactor-and whole tissue-based studies can help bridging the current gap between in vitro and in vivo studies.
Cost, or actually return-on-investment, is another important aspect to consider. In vitro studies can be relatively cheap, but their ability to predict the in vivo response to a treatment is currently low, as evidenced by a recent multi-center analysis which showed a surprisingly low correlation between in vitro and in vivo tests of biomaterials for bone regeneration. 68 The authors of the study have concluded that both standardization of in vitro and in vivo protocols, and the testing of regenerative strategy robustness against donor variation will contribute to improve the in vitro and vivo correlation. As for the standardization of in vivo experiments, this is a hot topic in the osteoarthritis research field. For instance, recommendations on preclinical models of osteoarthritis have been made in 2010 and further guidelines have been more recently proposed by the group of Little et al. [69] [70] [71] Notably, a checklist to be used prior to starting experiments has been proposed. 71 Such checklist could be implemented in the Design and Execution of Protocols for Animal Research and Treatment (DEPART) to make sure that guidelines on animal research, such as the "Animals in Research: Reporting In Vivo Experiments" (ARRIVE) which many journal have adopted, are met. To reduce the in vitro-in vivo gap, special care needs to be also taken in the choice of the animal model. While many studies are still performed on small rodent models, there is a large gap in the translation of successful therapies from mice to humans. 72 Importantly not only breeds play a role, but even environmental factors such as nutrition, bedding and exposure to light have been shown to have a strong impact on the outcome of rodent experiments. 73 Humanized mice models represent an interesting solution to fasten translation, 74 but there is still a long way to go. As for the return-on-investment, and just as an example, in Switzerland the cost for a large animal model (e.g., sheep) in vivo study is in the range of 10,000 CHF (equivalent to $9,930 $ or $9,140 s) per animal. So, with a budget of 100,000 CHF ($100,000 $ or $90,000 s), a study with 10 animals can be performed, which can be quite limited, depending on how many treatment groups can be tested in each animal and the analyses to be performed. Now, with the same budget a four-station bioreactor system (including control unit and software) can be built, which will allow a virtually unlimited number of experiments to be conducted.
The importance of in vivo studies to investigate possible side effects is unquestionable as it is not possible to replicate in vitro the whole range of events occurring in vivo. Increasing knowledge of the relationships between different body functions and growing wiliness to replace animal models have set the ground for the development of more predictive in vitro as well as in silico models.
75,76

RELEVANCE OF BIOREACTOR-BASED MODELS TO THE 3Rs
In 1959, Russel and Burch proposed the 3Rs initiative ("replacement," "reduction," "refinement") aiming at replacing animal testing by other methods, reducing to the minimum the numbers of animals used, refining the experiments to minimize animal distress and improve animal welfare. 77 This initiative has been integrated in national and international legislations regulating the use of animals in scientific procedures. Further information can be found on the national 3R websites, such as https://www.nc3rs.org.uk/the-3rs in the United Kingdom or http://3rs.ccac.ca/en/ in Canada.
A successful implementation of the 3Rs initiative starts with a conscientious study design of the experiments 71, 78 and the use of alternative models (e.g., in vitro, ex vivo) to animal testing whenever possible. We believe that ex vivo bioreactor-based models may represent such alternative systems that can help identifying the bottleneck of certain approaches prior moving to in vivo testing and thus contribute to minimize the number of animals needed. In addition, more complex, bioreactor-based in vitro models (e.g., by using organs from large animals, such as the intervertebral disc) may also help to better predict the in vivo response, including in large animal models. When animal testing cannot be replaced, ex vivo cultures and bioreactors may contribute to the identification of the appropriate number of animals needed to find biologically-meaningful and statisticallysignificant differences among groups. 79, 80 Following a systematic review of previous animal studies to identify the most adequate animal species and model, 81, 82 pilot studies could be conducted ex vivo with explants from animals of the same species already unrolled in other, unrelated studies.
To address the last "R" of the 3Rs, several aspects are important to guarantee animal welfare, such as surgical intervention performed by veterinarians specialized in surgery, familiarity with the behavior of the species/strain by the animal caretakers in order to recognize distress/pain, adequate housing conditions (e.g., for immunodeficient mice). Finally, to close the loop, animal experiments need to be reported in a standardized, systematic way (e.g., ARRIVE guidelines) to allow further analysis in the future. 71 The Food and Drug Administration (FDA), the National Institute of Health (NIH) 83 (https://www.nih. gov/research-training/rigor-reproducibility/principlesguidelines-reporting-preclinical-research), many scientific journals, and the Orthopedic Research Society (ORS) have all been playing an important role in the promotion of rigorous principles and guidelines in preclinical research in the United States and beyond. A strong increase in the use of alternative models to animal testing is foreseeable for coming years.
CONCLUSIONS AND FUTURE CHALLENGES
While there is no animal model that fully replicates a human disease, in vitro, ex vivo, and in vivo models can be used to address specific issues related to the diseased condition. The most appropriate model will depend on the research question to be addressed and advantages and limitations of each model need to be carefully considered in the design of the experiments. The tissue origin needs to be carefully considered as there are differences in cell population, tissue composition, anatomy, development, physiology, and mechanical properties between animal and human species. 84 Bioreactor tissue/organ cultures allow the preservation of musculoskeletal tissue architecture and function under physiological mechanical stimuli. Bioreactors can help to identify crucial factors involved in normal tissue development, homeostasis, injury, and pathology and can be used to screen novel treatments in a highly-relevant environment. Ex vivo whole organ culture models from large animals will provide a more representative response than conventional 2D (or even 3D) cell cultures and represent an additional, costeffective investigational tool to complete small, large, and human clinical trial experiments.
Culture of human biological samples under defined nutritional and mechanical conditions (i.e., in bioreactor systems) may bring more relevant results for the translation of new therapies to the clinics compared to many of the current in vitro, ex vivo, and in vivo experimental setups, as highlighted by the "Bioreactor Relevance scale" (Fig. 2) . Although challenging (in terms of ethical approval, patient consent, sample number, and variability), this is possible 26 and leaves the debate open on whether it is more ethical to use animal models or human biological tissue donation when targeting human pathologies. 85 In fact, there is evidence that animal models have limited predictive value for assessing both safety and efficacy of treatments for human diseases, 72 with an unacceptable high cost to benefit ratio and unnecessary risks for the patients. Hence, there is an urgent need to promote alternatives to animal research.
Research involving human tissue would benefit from easier legislation and wider support in the future. Medical progress in the identification of patient sub-populations for specific musculoskeletal disease will contribute to optimize experimental models and in turn help the development of targeted treatments. A very promising development is represented by bioreactor cultures of decellularized and recellularized organs, which has been widely studied in the field of organ transplantation (e.g., liver). 86, 87 For the future, there is a high need for predictive tools based on experimentally validated in silico models, and bioreactors (especially in high-throughput platforms) can provide a useful tool to validate computational models. 88 A huge challenge is the development of models capable of linking in vitro, ex vivo, in vivo outcomes. The organ on chip technology may provide a remarkable tool for this purpose. 89 Last but not least, bioreactors have a role to play in the development of the most suitable rehabilitation therapy following injury or disease and will hopefully also contribute to the establishment of preventive physical therapies adapted to the risk factor (e.g., scoliosis, autologous chondrocyte implantation, obesity, etc.). Bioreactor relevance scale of two-dimensional (2D), three-dimensional (3D), organ, and animal studies and arbitrary added relevance when using human cells/tissues for such experiments.
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